Trimipramine Maleate



Trimipramine Maleate





(trye mi’ pra meen)

Apo-Trimip (CAN), Surmontil

PREGNANCY CATEGORY C


Drug Classes

Antidepressant

TCA (tertiary amine)


Therapeutic Actions

Mechanism of action unknown; the TCAs are structurally related to the phenothiazine antipsychotics (eg, chlorpromazine); TCAs inhibit the presynaptic reuptake of the neurotransmitters norepinephrine and serotonin; anticholinergic at CNS and peripheral receptors; the relation of these effects to clinical efficacy is unknown.


Indications



  • Relief of symptoms of depression (endogenous depression most responsive); sedative effects of tertiary amine TCAs may be helpful in patients whose depression is associated with anxiety and sleep disturbance


  • Unlabeled use: Duodenal ulcers



Available Forms

Capsules—25, 50, 100 mg


Dosages

Adults



  • Hospitalized patients: Initially, 100 mg/day PO in divided doses. Gradually increase to 200 mg/day as required. If no improvement in 2–3 wk, increase to a maximum dose of 250–300 mg/day.


  • Outpatients: Initially, 75 mg/day PO in divided doses. May increase to 150 mg/day. Do not exceed 200 mg/day. Total daily dosage may be administered at bedtime. Maintenance dose is 50–150 mg/day given as a single dose at bedtime. After satisfactory response, reduce to lowest effective dosage. Continue therapy for 3 mo or longer to lessen possibility of relapse.

Pediatric patients 12 yr and older

50 mg/day PO with gradual increases up to 100 mg/day.


Pediatric patients younger than 12 yr

Not recommended.

Geriatric patients

50 mg/day PO with gradual increases up to 100 mg/day PO.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jul 21, 2016 | Posted by in NURSING | Comments Off on Trimipramine Maleate

Full access? Get Clinical Tree

Get Clinical Tree app for offline access